Azaya Launches New CDMO
Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing.
Azaya Therapeutics, a biopharmaceutical company focused on focused on developing cancer treatments through its nanotechnology platform, announced the launch of a new division, Parexo Labs, as a CDMO providing chemical testing and liposomal manufacturing services to outside organizations. Parexo Labs will offer capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles.
“Azaya Therapeutics has over 10 years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the rollout of Parexo Labs,” said Mike Dwyer, Azaya Therapeutics CEO and president, in a company press release. “Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.”
Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing, chemical characterization and other analyses. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
